Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]SHR6390 Mass Balance Study
NCT04616742Phase 1Completed
- Sponsor
- Hengrui
- Start
- Nov 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by Hengrui. Primary endpoints: Quantitive analysis of whole radioactivity of excrement at Day 21, Concentrations of SHR6390 in plasma at Day 7 and 1 more. Started Nov 2020; status: completed.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04616742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616742.